Poly I:C and STING agonist-primed DC increase lymphoid tissue polyfunctional HIV-1-specific CD8
CD8+ T cell
dendritic cell
hBLT mouse
lymphoid tissue
vaccine
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
19
11
2021
received:
12
07
2021
accepted:
14
12
2021
pubmed:
23
12
2021
medline:
6
5
2022
entrez:
22
12
2021
Statut:
ppublish
Résumé
Effective function of CD8
Identifiants
pubmed: 34935145
doi: 10.1002/eji.202149502
doi:
Substances chimiques
AIDS Vaccines
0
Adjuvants, Immunologic
0
HIV Core Protein p24
0
Poly I-C
O84C90HH2L
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
447-461Subventions
Organisme : NIAID NIH HHS
ID : R21 AI140930
Pays : United States
Informations de copyright
© 2022 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
O'Connell, R. J., Kim, J. H., Corey, L. and Michael, N. L., Human immunodeficiency virus vaccine trials. Cold Spring Harb. Perspect. Med. 2012. 2: a007351.
Gray, G. E., Laher, F., Lazarus, E., Ensoli, B. and Corey, L., Approaches to preventative and therapeutic HIV vaccines. Curr. Opin. Virol. 2016. 17: 104-109.
O'Keeffe, M., Mok, W. H. and Radford, K. J., Human dendritic cell subsets and function in health and disease. Cellular and molecular life sciences: CMLS. 2015.
Martin-Gayo, E., Gao, C., Chen, H. R., Ouyang, Z., Kim, D., Kolb, K. E. et al., Immunological fingerprints of controllers developing neutralizing HIV-1 antibodies. Cell Rep. 2020. 30: 984-996.e4.
Bol, K. F., Schreibelt, G., Gerritsen, W. R. and de Vries, I. J., Figdor, C. G., Dendritic cell-based immunotherapy: state of the art and beyond. Clin. Cancer Res. 2016. 22: 1897-1906.
Ide, F., Nakamura, T., Tomizawa, M., Kawana-Tachikawa, A., Odawara, T., Hosoya, N. et al., Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J. Med.Virol. 2006. 78: 711-718.
Kundu, S. K., Engleman, E., Benike, C., Shapero, M. H., Dupuis, M., van Schooten, W. C. et al., A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res. Hum. Retroviruses 1998. 14: 551-560.
Gandhi, R. T., O'Neill, D., Bosch, R. J., Chan, E. S., Bucy, R. P., Shopis, J. et al., A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009. 27: 6088-6094.
García, F., Climent, N., Guardo, A. C., Gil, C., León, A., Autran, B., Lifson, J. D., Martínez-Picado, J., Dalmau, J., Clotet, B., Gatell, J. M., Plana, M. and Gallart, T., A dendritic cell-based vaccine elicits T Cell responses associated with control of HIV-1 replication. Science Translational Medicine. 2013. 5. http://doi.org/10.1126/scitranslmed.3004682
Coelho, A. V., de Moura, R. R., Kamada, A. J., da Silva, R. C., Guimaraes, R. L., Brandao, L. A. et al., Dendritic cell-based immunotherapies to fight HIV: how far from a success story? a systematic review and meta-analysis. Int. J. Mol. Sci. 2016. 17: 1985.
Martin-Gayo, E., Buzon, M. J., Ouyang, Z., Hickman, T., Cronin, J., Pimenova, D. et al., Potent cell-intrinsic immune responses in dendritic cells facilitate HIV-1-specific t cell immunity in HIV-1 elite controllers. PLoS Pathog. 2015. 11: e1004930.
Gao, D., Wu, J., Wu, Y. T., Du, F., Aroh, C., Yan, N. et al., Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 2013, 341: 903-906.
Habjan, M. and Pichlmair, A., Cytoplasmic sensing of viral nucleic acids. Curr. Opin. Virol. 2015, 11: 31-37.
Ma, Z. and Damania, B., The cGAS-STING defense pathway and its counteraction by viruses. Cell Host & Microbe 2016. 19: 150-158.
Almeida, J. R., Price, D. A., Papagno, L., Arkoub, Z. A., Sauce, D., Bornstein, E. et al., Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 2007. 204: 2473-2485.
Betts, M. R. and Harari, A., Phenotype and function of protective T cell immune responses in HIV. Curr Opin HIV AIDS 2008. 3: 349-355.
Zhao, C. and Zhao, W., TANK-binding kinase 1 as a novel therapeutic target for viral diseases. Expert Opin. Ther. Targets 2019. 23: 437-446.
Huang, X. L., Fan, Z., Borowski, L. and Rinaldo, C. R., Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity. J. Leukoc. Biol. 2008. 83: 1530-1540.
Nguyen, S., Deleage, C., Darko, S., Ransier, A., Truong, D. P., Agarwal, D. et al., Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8(+) T cells. Sci. Transl. Med. 2019. 11: eaax4077.
Fukazawa, Y., Lum, R., Okoye, A. A., Park, H., Matsuda, K., Bae, J. Y. et al., B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 2015. 21: 132-139.
Sui, Y., Gordon, S., Franchini, G. and Berzofsky, J. A., Nonhuman primate models for HIV/AIDS vaccine development. Curr. Protoc. Immunol. 2013. 102: 1-30.
Lan, P., Tonomura, N., Shimizu, A., Wang, S. and Yang, Y. G., Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 2006. 108: 487-492.
Marsden, M. D., Kovochich, M., Suree, N., Shimizu, S., Mehta, R., Cortado, R. et al., HIV latency in the humanized BLT mouse. J. Virol. 2012. 86: 339-347.
Wege, A. K., Melkus, M. W., Denton, P. W., Estes, J. D. and Garcia, J. V., Functional and phenotypic characterization of the humanized BLT mouse model. Curr. Top. Microbiol. Immunol. 2008. 324: 149-165.
Weichseldorfer, M., Heredia, A., Reitz, M., Bryant, J. L. and Latinovic, O. S., Use of humanized mouse models for studying HIV-1 infection, pathogenesis and persistence. Journal of AIDS and HIV Treatment 2020. 2: 23-29.
Stripecke, R., Münz, C., Schuringa, J. J., Bissig, K. D., Soper, B., Meeham, T. et al., Innovations, challenges, and minimal information for standardization of humanized mice. EMBO Mol. Med. 2020. 12: e8662.
Brainard, D. M., Seung, E., Frahm, N., Cariappa, A., Bailey, C. C., Hart, W. K. et al., Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J. Virol. 2009. 83: 7305-7321.
Dudek, T. E., No, D. C., Seung, E., Vrbanac, V. D., Fadda, L., Bhoumik, P. et al., Rapid evolution of HIV-1 to functional CD8(+) T cell responses in humanized BLT mice. Sci. Transl. Med. 2012. 4: 143ra98.
Garcia, F., Lejeune, M., Climent, N., Gil, C., Alcami, J., Morente, V. et al., Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis. 2005. 191: 1680-1685.
Kloverpris, H., Karlsson, I., Bonde, J., Thorn, M., Vinner, L., Pedersen, A. E. et al., Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009. 23: 1329-1340.
Claiborne, D. T., Dudek, T. E., Maldini, C. R., Power, K. A., Ghebremichael, M., Seung, E. et al., Immunization of BLT humanized mice redirects T cell responses to Gag and reduces acute hiv-1 viremia. J. Virol. 2019. 93.
Betts, M. R., Nason, M. C., West, S. M., De Rosa, S. C., Migueles, S. A., Abraham, J. et al., HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006. 107: 4781-4789.
Migueles, S. A., Laborico, A. C., Shupert, W. L., Sabbaghian, M. S., Rabin, R., Hallahan, C. W. et al., HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 2002. 3: 1061-1068.
Thompson, K. A., Strayer, D. R., Salvato, P. D., Thompson, C. E., Klimas, N., Molavi, A. et al., Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur. J. Clin. Microbiol. Infect. Dis. 1996. 15: 580-587.
Armstrong, J. A., McMahon, D., Huang, X. L., Pazin, G. J., Gupta, P., Rinaldo, C. R., Jr. et al., A phase I study of ampligen in human immunodeficiency virus-infected subjects. J. Infect. Dis. 1992. 166: 717-722.
Miller, E., Spadaccia, M., Sabado, R., Chertova, E., Bess, J., Trubey, C. M. et al., Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. Vaccine 2015. 33: 388-395.
Apostólico, J. S., Lunardelli, V. A. S., Yamamoto, M. M., Cunha-Neto, E., Boscardin, S. B. and Rosa, D. S., Poly(I:C) potentiates T cell immunity to a dendritic cell targeted HIV-multiepitope vaccine. Front. Immunol. 2019. 10: 843.
Cheng, L., Wang, Q., Li, G., Banga, R., Ma, J., Yu, H. et al., TLR3 agonist and CD40-targeting vaccination induces immune responses and reduces HIV-1 reservoirs. J. Clin. Invest. 2018. 128: 4387-4396.
Gómez, C. E., Nájera, J. L., Sánchez, R., Jiménez, V. and Esteban, M. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 2009. 27: 3165-3174.
Alvarez-Carbonell, D., Garcia-Mesa, Y., Milne, S., Das, B., Dobrowolski, C., Rojas, R. et al., Toll-like receptor 3 activation selectively reverses HIV latency in microglial cells. Retrovirology 2017. 14: 9.
Martin-Gayo, E., Cole, M. B., Kolb, K. E., Ouyang, Z., Cronin, J., Kazer, S. W. et al., A reproducibility-based computational framework identifies an inducible, enhanced antiviral state in dendritic cells from HIV-1 elite controllers. Genome Biol. 2018. 19: 10.
Lévy, Y., Thiébaut, R., Montes, M., Lacabaratz, C., Sloan, L., King, B. et al., Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. Eur. J. Immunol. 2014. 44: 2802-2810.
He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M. et al., Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. Nature 2016. 537: 412-428.
Leong, Y. A., Chen, Y., Ong, H. S., Wu, D., Man, K., Deleage, C. et al., CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. Nat. Immunol. 2016. 17: 1187-1196.
Murooka, T. T., Deruaz, M., Marangoni, F., Vrbanac, V. D., Seung, E., von Andrian, U. H. et al., HIV-infected T cells are migratory vehicles for viral dissemination. Nature 2012. 490: 283-287.
Karpel, M. E., Boutwell, C. L. and Allen, T. M., BLT humanized mice as a small animal model of HIV infection. Curr. Opin. Virol. 2015. 13: 75-80.
Zeng, M., Haase, A. T. and Schacker, T. W., Lymphoid tissue structure and HIV-1 infection: life or death for T cells. Trends Immunol. 2012. 33: 306-314.
Sanchez, J. L., Hunt, P. W., Reilly, C. S., Hatano, H., Beilman, G. J., Khoruts, A. et al., Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions. J. Infect. Dis. 2015. 211: 1068-1075.
Giménez, E., Blanco-Lobo, P., Muñoz-Cobo, B., Solano, C., Amat, P., Pérez-Romero, P. et al., Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. J. Gen. Virol. 2015. 96: 2822-2831.
Grifoni, A., Costa-Ramos, P., Pham, J., Tian, Y., Rosales, S. L., Seumois, G. et al., Cutting edge: transcriptional profiling reveals multifunctional and cytotoxic antiviral responses of zika virus-specific CD8(+) T cells. J. Immunol. 2018. 201: 3487-3491.
Cossarizza, A., Chang, H. D., Radbruch, A., Acs, A., Adam, D., Adam-Klages, S. et al., Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur. J. Immunol. 2019. 49: 1457-1973.